Description

FDA-approved intravenous and intra-articular therapy available to treat non-infectious synovitis associated with osteoarthritis in horses. Hyaluronate sodium is the glycosaminoglycan present in normal joint fluid. It is produced by a patented biofermentation process that results in such purity that it can be given intravenously for immediate bioavailability.

NexHA, a generic form of Hyaluronate Sodium has now been approved by the FDA is a formulation of purified hyaluronate sodium that can be administered to horses by intravenous or intra-articular injection.

Usage

Hyaluronate sodium is used in the healing of degenerative joint disease. One major function is the regulation of normal cell constituents that decrease the impact of exudation, enzyme release, and subsequent degradation of joint integrity. Injected directly into the joint pouch, it enhances the healing of the inflamed synovium by restoring lubrication of the joint fluid. It also exerts an anti-inflammatory action.

NexHA, the generic form of hyaluronate sodium is indicated in the treatment of joint dysfunction of the carpus or fetlock in horses due to non-infectious synovitis associated with equine osteoarthritis. Hyaluronate sodium acts as a replacement for synovial fluid, the naturally occurring lubricant in articular joints.

Dosage and Administration

Hyaluronate Sodium
Method	Dosage	Concentration	Period	Duration
IV injection	4 ml	10 mg/ml	Weekly	Up to 3 treatments
Intra-Articular injection1	2 ml	10 mg/ml	Weekly	Up to 3 treatments
Notes: Federal law restricts this drug to use by or on the order of a licensed veterinarian. Extra-label use of drugs in treating animals is allowable only by licensed veterinarians within the context of a valid veterinarian-client-patient relationship, and does not include drug use in treating animals by the layman (except under the supervision of a licensed veterinarian). 1Stall rest on days following treatment before gradually resuming normal activity.

Side Effects

No local or systemic side effects have been observed in clinical trials with either intravenous or intra-articular injections.

Precautions

Radiographic evaluation should be used in cases of acute lameness to rule out fractures or other serious conditions.

Precautions should be followed as to injection technique and sterility for prevention of swelling or infection.

Care should be taken to avoid scratching the cartilage surface with the tip of the injection needle.

For intravenous administration, use asceptic technique and inject slowly into the jugular vein.

Horses should be given stall rest after treatment and before gradually resuming normal activity.

Federal law restricts this drug to use by or on the lawful written or oral order of a licensed veterinarian.

Product is not for use in horses intended for human consumption.

Interactions

None noted.

Overdose

Check manufacturer's information.